Towards
Next Generation
Bioscience

May 03—May 04
2018

HALLE 02
ZOLLHOFGARTEN 2
69115 HEIDELBERG
GERMANY

About XSEED CON

XSEED CON is a 2-day event offering cross-pollination between researchers from distinct disciplines (nanotechnology, bioinformatics, genetics, biophysics, cell biology), to go beyond the current boundaries in biomedical research, and to plant intellectual seeds about future technologies in the minds of all participants.

Scientists from both academia and industry will bridge the gap between the two worlds.

Keynote Speakers

Image: Elena Cattaneo – University Milan, Italy

Elena Cattaneo

University Milan, Italy

Read CV

Close

Elena Cattaneo

University Milan, Italy

Elena Cattaneo is director of the Laboratory of stem cell biology and pharmacology of neurodegenerative diseases at the Department of Biosciences (www.cattaneolab.it) as well as co‐founder and first appointed Director of UniStem (www.unistem.it), the Centre for Stem Cell Research of the University of Milano. The main research theme of her lab is neural stem cells and the molecular pathophysiology of Huntington’s Disease (HD).

Her studies on neural stem cells and Huntington’s disease saw her awarded with numerous prizes. In 2006 was nominated Cavaliere Ufficiale (Knight) of the Italian Republic, and in 2013 was appointed senator for life by Italy’s president, Giorgio Napolitano. She was also named Stem Cell Person of the Year in 2013 by Paul Knoepfler and the readers of his blog, and awarded the ISSCR Public Service Award in 2014 , with Paolo Bianco and Michele De Luca, for “their recent involvement in public debate and policy-making in Italy, championing rigorous scientific and medical standards and stringent regulatory oversight in the introduction of new stem cell treatments into the clinic.”

Elena has published 105 papers in peer-reviewed journals, has given more than 200 invited lectures, and is very active in organizing professional development and outreach events – for both the scientific community and lay public.

Close

Michael Hayden

Teva, Israel

Dr. Hayden joined Teva as President of Global R&D and Chief Scientific Officer in 2012. He is also currently the Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine. He is also the founder and Senior Scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia.

Prior to joining Teva, he founded three biotechnology companies (NeuroVir, Aspreva Pharmaceuticals and Xenon Pharmaceuticals Inc.) and served as Chief Scientific Officer of Xenon from 2000 to 2012. He also served as a director of Med Biogene Inc. from 2010 to 2011.

He has received numerous awards, including the Canada Gairdner Wightman Award in 2011, the Order of Canada Award in 2010, the highest honor that Canada can give its citizens for exceptional achievement, and the Distinguished Scientist Award of the Canadian Society of Clinical Investigation in 1998 and in 2008 he was named Canada’s Health Researcher of the Year.

Michael and his research group have identified 10 disease-causing genes which includes the identification of the major gene underlying high-density lipoprotein (HDL) in humans. Michael also identified the first mutations underlying Lipoprotein Lipase (LPL) Deficiency and developed gene therapy approaches to treat this condition.

Image: John P. Overington – Medicines Discovery Catapult, UK

John P. Overington

Medicines Discovery Catapult, UK

Read CV

Close

John P. Overington

Medicines Discovery Catapult, UK

During his studies in Bath and London, John developed automated approaches to protein modelling, contributing to the development of the programs COMPOSER and MODELLER; however, his major research was on sequence-structure relationships, exploring the constraints applied by the local physical environment of a residue in constraining mutational trajectory (JOY and HOMSTRAD). John then held a postdoctoral position at the Imperial Cancer Research Fund (now part of CRUK).

John then joined Pfizer (1992), originally as a computational chemist, progressing to a role where he led a multidisciplinary group combining rational drug design with structural biology. During this time, John explored the reasons for target/drug attrition and the falling productivity of the pharmaceutical industry. In 2000 John moved to a start-up biotech company, Inpharmatica, where he led the development of a series of computational and data platforms to improve drug discovery; these included the medicinal chemistry database StARLite. In 2008 John was central to the transfer of this database to the EMBL-EBI, where the successor is now known as the ChEMBL. More recently, the work extended into large-scale patent informatics with the Open patent database SureChEMBL. John then joined (2015) a London-based technology company – Stratified Medical/BenevolentAI. In this role, John was involved in development of novel data extraction and integration strategies, and integrating deep learning and other artificial intelligence approaches to drug target validation and drug optimisation.

Most recently John works as CIO at the UK’s Medicines Discovery Catapult, a UK non-profit organisation driving innovation and value creation in SMEs.

Image: William Shih – Harvard Medical School, Boston, USA

William Shih

Harvard Medical School, Boston, USA

Read CV

Close

William Shih

Harvard Medical School, Boston, USA

William Shih is Professor at the Department of Biological Chemistry, Molecular Pharmacology and Department of Cancer Biology at Harvard University. He is overseeing an effort to apply Synthetic Biology approaches to the development of self-assembling DNA nanostructures and devices for use in biomedical applications. He is overseeing an effort to apply Synthetic Biology approaches to the development of self-assembling DNA nanostructures and devices for use in biomedical applications. In addition to carrying genetic information, DNA is increasingly being explored for its use as a building material. This new process is called DNA origami because a long strand of DNA can be programmed to fold in on itself to create specific shapes, much as a single sheet of paper is folded to create a variety of designs in the traditional Japanese art. Using long biologically produced DNA strands to construct particles with precisely specified shapes, William is able to approximate a level of complexity that rivals that of the molecular machinery found in cells.

In 2008, William received a New Innovator Award from the National Institutes of Health, and in 2013, he was named as a Blavatnik National Awards Finalist.

Invited Speakers

Image: Christoph Bock – CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

Christoph Bock

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

Read CV

Close

Christoph Bock

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

Christoph Bock is a principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences.

His research focuses on dissecting the role of epigenetics in cancer and on developing high-throughput technologies for precision medicine.

He is also a guest professor at the Medical University of Vienna, scientific coordinator of the Biomedical Sequencing Facility at CeMM, and adjunct group leader for bioinformatics at the Max Planck Institute for Informatics.

He has received several research awards, including the Max Planck Society’s Otto Hahn Medal (2009), an ERC Starting Grant (2016-2021), and the Overton Prize of the International Society of Computational Biology (2017).

Image: Philippe Bousso – Pasteur Institute, Paris, France

Philippe Bousso

Pasteur Institute, Paris, France

Read CV

Close

Philippe Bousso

Pasteur Institute, Paris, France

Philippe Bousso, PhD is an immunologist heading the Dynamics of Immune Responses Unit at the Pasteur Institute.

During his PhD with Philippe Kourilsky, he characterized the composition and variability of TCR repertoires. He performed his postdoctoral work with Ellen Robey at UC Berkeley where he pioneered the use of two-photon imaging to study immune responses in vivo.

Since 2005, he is a principal investigator in the Department of Immunology at Pasteur. With the help of innovative functional imaging approaches, his research aims at understanding and manipulating immune responses in the context of disease pathogenesis.

Over the last years, his lab helped redefine the process of T cell activation in vivo. His work in the field of infectious diseases offered the first demonstration that effector cytokines were acting over extended distances in the infected tissue to effectively control intracellular pathogens. His lab also characterized a novel cellular pathway responsible for graft rejection.

Finally, in the context of tumor immunity, his group identified the distinct roles of T cells and NK cells in tumor cell killing, uncovered the mode of action of anti-CD20 therapy and the mechanism regulating the anatomical segregation of GVL and GVHD.

Philippe Bousso is an EMBO member, laureate of several prizes from the French Academy of Science and the French Academy of Medicine and awardee of an ERC Starting and an ERC Advanced Grant.

Image: Adrian Carter – Boehringer Ingelheim, Ingelheim am Rhein, Germany

Adrian Carter

Boehringer Ingelheim, Ingelheim am Rhein, Germany

Read CV

Close

Adrian Carter

Boehringer Ingelheim, Ingelheim am Rhein, Germany

Adrian Carter is a corporate vice president and global head of Discovery Research Coordination at Boehringer Ingelheim where he is responsible for guiding research policy, managing strategic and operational initiatives in research, and overseeing competitive intelligence activities. He graduated from the University of Wales in Cardiff with an honours degree in biology, has a Ph.D. in pharmacology from the Department of Medicine at the University of Nottingham, and an executive MBA from the University of Mainz.

His career at Boehringer Ingelheim spans more than 32 years including 8 years as head of neuropharmacology where he studied the neurobiology of dopamine, noradrenaline and acetylcholine release as well as the role of NMDA receptors and voltage-dependent sodium channels in health and disease. Adrian subsequently spent 10 years in business development where he led the negotiations for several large licensing collaborations, co-commercialization deals, and patent agreements.

Adrian represents Boehringer Ingelheim on the board of trustees for the Structural Genomics Consortium (SGC) and the Scientific and Medical Institute (NMI) in Reutlingen as well as the Innovative Medicines Strategy Priority Working Group of the European Federation of Pharmaceutical Industries and Associations.

Check out Adrian’s scientific contributions at https://www.researchgate.net/profile/Adrian_Carter2

Image: Robert Lucas – University of Manchester, UK

Robert Lucas

University of Manchester, UK

Read CV

Close

Robert Lucas

University of Manchester, UK

Prof. Lucas received a BSc in Biological Sciences from the University of York, and a PhD in Anatomy from the University of London under supervision of Andrew Loudon. Following post-doctoral training with Russell Foster at Department of Biology Imperial College London, he took his first academic position in the Faculty of Medicine, Imperial College before moving to the University of Manchester in 2003 where he is the GSK Professor of Neuroscience.

His research interests have developed from neuroendocrinology and chronobiology to photobiology and vision science as he has pursued interest in the ways that animals respond to visual stimuli. He has made important contributions to the discovery and elucidation of melanopsin-based photoreceptors in the mammalian retina and has seen these through to application in developing new metrics for light measurement and updates to visual display architecture.

He has also exploited his expertise in the opsin family of photopigments to develop optogenetic tools allowing photic control over G-protein signaling cascades and, particularly, vision restoration following retinal degeneration.

Image: Richard Marshall – GSK, UK

Richard Marshall

GSK, UK

Image: Serena Nik-Zainal – Sanger Institute, Hinxton,UK

Serena Nik-Zainal

Sanger Institute, Hinxton,UK

Read CV

Close

Serena Nik-Zainal

Sanger Institute, Hinxton,UK

Serena is a CRUK Advanced Clinician Scientist and explores patterns of mutations or mutational signatures that arise in human cells to understand how DNA damage and DNA repair processes contribute towards aging and cancer.

She is also an Honorary Consultant in Clinical Genetics. Serena hunts for mutation signatures in large cancer datasets using computational approaches. She explores these signatures through cell-based model systems and runs a clinical project, Insignia (www.mutationsignatures.org), recruiting patients with DNA repair/replication defects, aging syndromes, neurodegeneration, and people exposed to environmental/occupational mutagens, to understand mutational phenomena in these patients.

She is now focused on advancing the analytical frameworks of mutational signatures further and also translating them into clinical applications.

Image: Rienk Offringa – German Cancer Research Center, Heidelberg, Germany

Rienk Offringa

German Cancer Research Center, Heidelberg, Germany

Read CV

Close

Rienk Offringa

German Cancer Research Center, Heidelberg, Germany

Rienk started off as a molecular biologist, studying gene regulation in cancer, but when he witnessed the power of T-cell therapy in pre-clinical mouse models, he decided to focus his post-doctoral career on cancer immunotherapy.

After a post doc at Dana Farber Cancer Institute in Boston, he went back to his ‘alma mater’ in Leiden, The Netherlands, to head the Tumor Immunology Laboratory at Leiden University Medical Center.

Subsequently, he worked at Genentech Inc. in San Francisco, where he focused on the development of immunotherapeutic drugs.

After 4 years in Industry (in 2011), Rienk moved back to academia and back to Europe, by accepting a full professorship at University Hospital Heidelberg and DKFZ.

Currently he is running two labs, one focusing on pancreatic cancer and cancer immunotherapy, and a second dedicated to the development of cancer immunotherapy drugs, co-funded by DKFZ and Bayer Healthcare.

Image: Lucas Pelkmans – University of Zurich, Switzerland

Lucas Pelkmans

University of Zurich, Switzerland

Read CV

Close

Lucas Pelkmans

University of Zurich, Switzerland

Current and recent Positions

  • 01.2013 – present Chairman Scientific Executive Board, SystemsX.ch
  • 07.2010 – present Full Professor & Ernst Hadorn Chair, Institute of Molecular Life Sciences, University of Zurich.
  • 07.2010 – present Faculty member Faculty of Sciences, University of Zurich
  • 02.2007 Co-founder of 3-V Biosciences GmbH & Inc., Zürich and Palo Alto, CA.
  • 07.2005 – 06.2010 Assistant Professor Institute of Molecular Systems Biology, ETH Zurich.
  • 07.2005 – 06.2010 Faculty member Department of Biology, ETH Zurich
  • 06.2003 – 06.2005 Postdoctoral Fellow at the Max Planck Institute of Molecular Cell Biology and Genetics, Dresden

Honours and Awards

  • 2010 Ernst Hadorn Foundation-endowed Chair
  • 2008 Nomination for MIT Technology Review top 35 of the world’s leading Young Innovators under 35 of age (TR35)
  • 2005 Top 10 most-cited paper in cell biology in Europe published between 2000 – 2002 (Laborjournal)
  • 2005 European Young Investigator Award. Top 25 of Europe’s Young Scientists (over all sciences) awarded with a 5-year research grant.
  • 2005 SNF FörderungsProfessur. Independent research professorship for 4 (+1) years from the Swiss National Science Foundation.
  • 2004 Marie Curie Fellow
Image: Eran Segal – Weizmann Institute, Israel

Eran Segal

Weizmann Institute, Israel

Read CV

Close

Eran Segal

Weizmann Institute, Israel

Eran Segal is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in the area of Computational and Systems biology. His group has extensive experience in machine learning, computational biology, probabilistic models, and analysis of heterogeneous high-throughput genomic data. His research focuses on Nutrition, Genetics, Microbiome, and Gene Regulation and their effect on health and disease. His aim is to develop personalized nutrition and personalized medicine.

Prof. Segal published over 120 publications, and received several awards and honors for his work, including the Overton prize, awarded annually by the International Society for Bioinformatics (ICSB) to one scientist for outstanding accomplishments in computational biology, and the Michael Bruno award. He was recently elected as an EMBO member and as a member of the young Israeli academy of science.

Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York.

Image: Frank Vollmer – University of Exeter, UK

Frank Vollmer

University of Exeter, UK

Read CV

Close

Frank Vollmer

University of Exeter, UK

Frank Vollmer is a Professor of Biophysics at the Living Systems Institute, University of Exeter, UK. Prof Vollmer pioneers optical technology to study processes at the nanoscale.

He held several appointments at leading US institutions including Instructor in Medicine at Harvard Medical School.

Before moving to the LSI in 2016, he held the position of Research Group Leader at the Max Planck Institute for the Science of Light.

In 2017 Prof Vollmer was awarded the Royal Society Wolfson Research Merit Award.

Program

  • Welcome
    08:30 – 09:30 Registration and Welcome Coffee
    09:30 – 10:00 Welcome Note

    Christian Tidona,
    Managing Director BioMed X

  • Session I · Cells
    10:00 – 10:45 Keynote – Neurons from Stem Cells for Huntington’s Disease Research: Combining Genetics with Cell Biology and Evolution

    Elena Cattaneo,
    University Milan

    10:45 – 11:15 Coffee Break
    11:15 – 11:40 Presentation – Development of Next-Generation Immune Checkpoint Inhibitors in the Context of the DKFZ-Bayer Alliance

    Rienk Offringa,
    German Cancer Research Center

    11:40 – 12:05 Presentation – Methods for Epigenome Mapping and CRISPR Single-cell Sequencing

    Christoph Bock,
    CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences

    12:05 – 12:30 Presentation

    Richard Marshall,
    GSK

    12:30 – 14:30 Lunch & Poster Session
  • Session II · Molecules
    14:30 – 14:55 Presentation – Passive Noise Filtering by Cellular Compartmentalization

    Lucas Pelkmans,
    University of Zurich

    14:55 – 15:20 Presentation – Optoplasmonic Sensing of Protein Dynamics

    Frank Vollmer,
    University of Exeter

    15:20 – 15:55 Presentation
    15:55 – 16:30 Coffee Break
    16:30 – 17:30 Research Telegrams (6×10 min) + Poster Award
    17:30 – 18:15 Keynote – Lego-Style Construction of Future Therapeutics From DNA

    William Shih,
    Harvard Medical School

  • Conference Dinner & Party
    19:30 Conference Dinner & Party
    Venue: River Boat MS Königin Silvia, Neckarstaden 25, 69117 Heidelberg
  • Session III · Systems
    09:00 – 09:45 Keynote – Data Reliability – Is Public Data Reliable Enough for Systems Medicine?

    John Overington,
    Medicines Discovery Catapult, UK

    09:45 – 10:10 Presentation – Advancing the Field of Mutational Signatures: Clinical Applications

    Serena Nik-Zainal,
    Sanger Institute, UK

    10:10 – 10:35 Presentation – Personalizing Treatments Using Microbiome and Clinical Data

    Eran Segal,
    Weizmann Institute, Israel

    10:35 – 11:00 Coffee Break
  • Session IV · Light
    11:00– 11:25 Presentation – Animal Photoreception: New Concepts and Applications

    Robert Lucas,
    University of Manchester

    11:25 – 11:50 Presentation – Decoding Immune Responses to Cancer and Infection Using Intravital Imaging

    Philippe Bousso,
    Pasteur Institute

    11:50 – 12:15 Presentation
    12:15– 13:30 Lunch
  • Session V · Interface Academia - Industry
    13:30 – 14:15 Keynote – Innovation and Creativity in Drug Development

    Michael Hayden,
    TEVA

    14:15 – 14:45 Presentation – R&D Productivity in the Pharmaceutical Industry

    Adrian Carter,
    Boehringer Ingelheim

    14:45 – 15:00 Coffee Break
    15:00 – 16:00 Panel Discussion “Industry Meets Academia”

    Adrian Carter,
    Boehringer Ingelheim

    Michael Hayden,
    TEVA

    Rienk Offringa,
    German Cancer Research Center

    Christian Tidona
    BioMed X

    16:00 – 16:15 Farewell

    Christian Tidona,
    Managing Director BioMed X

Venue

Halle 02
Zollhofgarten 2
69115 Heidelberg
Germany

Open in Google Maps

Register

XSEED CON is a unique conference format across different disciplines in the life sciences making this event an unrivaled forum for scientists from academia and industry to discuss new disruptive innovations.

Early bird deadline for registration ends February 15th, 2018.

Image of

Close